Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Forxiga as add-on to insulin in type 1 diabetes
NCT02325206Phase 1Completed
- Sponsor
- Kinderkrankenhaus Auf der Bult
- Start
- Dec 2014
- Primary completion
- Dec 2015
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dapagliflozin in type 1 diabetes mellitus (T1D), sponsored by Kinderkrankenhaus Auf der Bult. Primary endpoint: Reduction of intravenous insulin dose at 24 hours. Started Dec 2014; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02325206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02325206.